Privacy in Biomarker Governance Accountability Doctrine

Introduction

Privacy in biomarker governance accountability doctrine concerns the legal principles that require hospitals, laboratories, biotechnology companies, pharmaceutical researchers, and public authorities to handle biological information responsibly. Biomarkers include measurable biological indicators such as hormones, proteins, blood glucose levels, genetic variations, and substances associated with disease.

These indicators may reveal a person's current health, future disease risks, treatment response, or inherited characteristics. Consequently, misuse of biomarker information can result in privacy violations, discrimination, unauthorised profiling, and loss of personal autonomy.

The accountability doctrine requires organisations not only to respect privacy but also to demonstrate that their data-handling practices comply with applicable legal standards. Although no single Indian statute establishes a separate doctrine specifically for biomarker governance, its foundations can be found in constitutional privacy law, data-protection legislation, medical confidentiality, and research ethics.

Legal Framework in India

Article 21 of the Constitution protects the fundamental right to privacy, while Article 14 provides protection against arbitrary state action. In Justice K.S. Puttaswamy (Retd.) v. Union of India (2017), the Supreme Court recognised that privacy includes informational autonomy and requires appropriate safeguards against unjustified intrusion.

Indian Kanoon

The Digital Personal Data Protection Act, 2023, and the Digital Personal Data Protection Rules, 2025, provide a framework for processing digital personal data. Whether particular biomarker information falls within the framework depends on identifiability, the nature of processing, applicable exemptions, and the relevant commencement provisions. The Rules were notified in November 2025 with phased commencement.

Press Information Bureau+2

Key accountability obligations include lawful processing, appropriate notice and consent where required, reasonable security safeguards, compliance with applicable data-principal rights, and effective grievance mechanisms.

Important Case Laws

*1. Justice K.S. Puttaswamy (Retd.) v. Union of India (2017)

The Supreme Court unanimously recognised privacy as a fundamental right under the Constitution. The judgment established that an invasion of privacy must satisfy legality, a legitimate state aim, and proportionality.

Relevance: This decision provides the constitutional foundation for biomarker privacy. Public authorities handling identifiable health data must have a lawful basis and respect constitutional safeguards. Its reasoning also supports the importance of transparency, data minimisation, security, and accountability in biological research.

Indian Kanoon

*2. K.S. Puttaswamy v. Union of India (2018)

The Supreme Court examined Aadhaar's biometric identification framework, including the collection, use, retention, and disclosure of biometric information. It upheld the scheme in substantial part while imposing limitations on certain aspects of its operation.

Relevance: The judgment illustrates why sensitive biological identifiers require clear legal authority, purpose restrictions, and effective safeguards. Although Aadhaar biometrics differ from medical biomarkers, the case offers important principles for responsible biological-data governance.

Indian Kanoon

*3. Mr. X v. Hospital Z (1998)

The Supreme Court considered the disclosure of a patient's HIV-positive status to his prospective spouse. It recognised medical confidentiality but found disclosure justified in the circumstances of the case to protect the prospective spouse's interests.

Relevance: The case demonstrates that medical confidentiality must be balanced against legally relevant health interests. Biomarker results indicating serious risks to another person may raise similar questions, but disclosure must be assessed under the applicable law and should not be treated as automatically permissible.

Major Challenges in Accountability

Informed consent: Individuals should understand the purpose of biomarker testing and the intended use of their information.

Secondary use: Data collected for diagnosis should not automatically be reused for unrelated commercial research.

Data security: Laboratories and healthcare institutions must protect records against unauthorised access, loss, and disclosure.

Discrimination: Biological information could be misused in employment, insurance, or other decisions.

Re-identification: Apparently anonymous biological datasets may reveal identities when combined with other information.

Institutional responsibility: Organisations should maintain access controls, audit records, complaint procedures, and appropriate remedies for violations.

Conclusion

Privacy in biomarker governance accountability doctrine combines constitutional protection, data-protection obligations, medical confidentiality, and institutional responsibility. Puttaswamy establishes the constitutional foundation, the Aadhaar judgment provides relevant principles for biometric safeguards, and Mr. X v. Hospital Z illustrates the balance between confidentiality and justified disclosure.

An effective governance framework should ensure lawful processing, appropriate consent, limited data collection, secure storage, controlled disclosure, independent oversight, and effective remedies. These safeguards help promote scientific and medical innovation while protecting individual dignity, autonomy, and informational privacy.